BIOGEN INC. Restructuring and Related Cost, Incurred Cost
BIOGEN INC. (BIIB) reported Restructuring and Related Cost, Incurred Cost of $300.00 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2025-07-31
- 2025-06-30: Restructuring and Related Cost, Incurred Cost 6 month $300.00M.
| Period end | Restructuring and Related Cost, Incurred Cost 6 month |
|---|---|
| 2025-06-30 | $300.00M 10-Q · filed 2025-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |